Drug profile

The FDA adverse-event record for Indoxacarb

50 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Indoxacarb. See the species affected, top reactions, and outcomes below.

50
adverse-event reports
2.0%
death-coded share
Dog
most-reported species
10
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
50
Total Reports
1
Deaths Reported
2.0%
Death Rate

Active Ingredients

Indoxacarb

Administration Routes

TopicalUnknownOralCutaneous

Species Affected

Dog 36
Cat 14

Most Affected Breeds

Domestic Shorthair 10
Domestic Mediumhair 3
Retriever - Golden 3
Shepherd Dog - German 3
Dog (other) 3
Retriever - Labrador 2
Chihuahua 2
Terrier - Bull - American Pit 2
Terrier - Rat 2
Cat (unknown) 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 10
Emesis 8
Anorexia 5
Lack of efficacy - NOS 5
Vomiting 5
Lack of efficacy (ectoparasite) - flea 4
Other abnormal test result NOS 4
INEFFECTIVE, HEARTWORM LARVAE 4
Ataxia 3
Anaemia NOS 3
Gagging 2
UNPALATABLE 2

Outcome Breakdown

Outcome Unknown
25 (50.0%)
Recovered/Normal
15 (30.0%)
Ongoing
9 (18.0%)
Euthanized
1 (2.0%)

Indoxacarb Adverse Event Insights

50 reports name Indoxacarb; 1 recorded a death outcome (2.0% of reported events, not a population-level mortality rate). Active ingredient: Indoxacarb. Administration routes: Topical, Unknown, Oral, Cutaneous.

By species: Dog (36 reports), Cat (14 reports). By breed: Domestic Shorthair (10), Domestic Mediumhair (3), Retriever - Golden (3).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (10), Emesis (8), Anorexia (5), Lack of efficacy - NOS (5). Outcome, 50 coded reports: Outcome Unknown leads at 50.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.